Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Why Amarin Stock Is Crushing It Today

TheMotleyFool

0 0

Why Amarin Stock Is Crushing It TodayPhoto, wide shot, wide-angle lens, Cleaning service, Midday, harsh overhead sunlight, directional sunlightt, photo by Marc Adamus: https://img.theapi.app/temp/66ee0081-ae60-418d-bd6e-b521f7433841.png

Shares of Amarin (NASDAQ: AMRN) were soaring 22.4% higher as of 11:44 a.m. EST on Tuesday. This big jump came after notes were released in advance of a U.S. Food and Drug Administration (FDA) advisory committee review that pointed to an increased likelihood that the drugmaker could win an expanded indication for Vascepa in reducing cardiovascular risk.

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee is scheduled to meet to review the expanded indication for Vascepa on Thursday. Notes from FDA staff related to the committee's review were released today.

Image source: Getty Images.

Source Fool.com

Like: 0

AMRN

Teilen